TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line—Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
Cyborg Score Rationale
TC BioPharm shows promise with differentiated gamma-delta T cell platform and proprietary manufacturing technology, but faces significant headwinds. The company was delisted from Nasdaq in March 2025 and finally removed from listing effective August 18, 2025 due to failure to maintain minimum bid price, creating liquidity and credibility challenges. Clinical progress in AML is encouraging but company remains pre-commercial with uncertain capital runway.
Top Insights
Company transitioned from Nasdaq to OTC Markets in March 2025 and was fully delisted effective August 18, 2025, significantly reducing liquidity and institutional accessibility
Phase 2b/3 pivotal trial underway for OmnImmune® in acute myeloid leukemia using proprietary CryoTC frozen product technology
Robust pipeline for solid tumors and significant IP/patent portfolio in CAR-gamma-delta T cell combinations with in-house manufacturing capabilities
Raised $6.0 million in August 2024 through public offering to fund ongoing clinical development
Named Competitors
CAR-T therapies — Chimeric antigen receptor T cell therapies
Gamma-delta T cell programs — Oncology immunotherapies including gamma-delta T cells
Allogeneic cell therapies — Allogeneic cell therapy platform for oncology
Recent Developments
(August 2025) Delisting finalized and removed from Nasdaq effective August 18, 2025
(April 2025) European patent granted for targeting of microbial, oncological, and viral indications using modified gamma-delta T cells
(March 2025) Nasdaq delisting suspension announced effective March 24, 2025 due to minimum bid price non-compliance
(February 2025) Implemented 1-for-20 reverse ADS split, changing ADS ratio from 200 ordinary shares to 4,000 ordinary shares per ADS
(August 2024) Closed $6.0 million upsized public offering
Open the full interactive TC BioPharm (Holdings) plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.